SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Newegg Commerce, Inc. (NEGG) (CIK 0001474627) (NEGG) — Mar 31, 2020

Newegg Commerce, Inc. (NEGG) (CIK 0001474627)
Date: March 31, 2020 · CIK: 0001474627 · Accession: 0000000000-20-002766

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-237358

Date
March 31, 2020
Author
William Mastrianna
Form
UPLOAD
Company
Newegg Commerce, Inc. (NEGG) (CIK 0001474627)

Letter

March 31, 2020 Ping Chen Chief Executive Officer Lianluo Smart Ltd. Room 611, 6th Floor, BeiKong Technology Building No. 10 Baifuquan Road, Changping District Beijing 102200, People’s Republic of China Re:Lianluo Smart Ltd. Registration Statement on Form F-1 Filed March 24, 2020 File No. 333-237358 Dear Mr. Chen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text
March 31, 2020
Ping Chen
Chief Executive Officer
Lianluo Smart Ltd.
Room 611, 6th Floor, BeiKong Technology Building
No. 10 Baifuquan Road, Changping District
Beijing 102200, People’s Republic of China
Re:Lianluo Smart Ltd.
Registration Statement on Form F-1
Filed March 24, 2020
File No. 333-237358
Dear Mr. Chen:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences